Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty.

Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, Chaussain JL

The Journal of clinical endocrinology and metabolism1 Jun 1999Cited by 105 (Europe PMC)

PMID10372696DOI10.1210/jcem.84.6.5647PepBankPUB-10372696

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In children with central precocious puberty treated with triptorelin, final height did not differ from genetic target height.
In plain wordsIn children with early puberty treated with triptorelin, final height did not differ from genetic target height.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFinal height versus target height
Study
n = 66
Comparator
Genetic target height
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
The FH SD score was close to 0 and was not different from the genetic target height.
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the long term results of 58 girls and 8 boys uniformly treated with triptorelin slow release formulation (Decapeptyl, triptorelin-SR) for CPP and compared their FH with predicted height before treatment and with the FH of a historical group of patients not treated with GnRH agonist.
Report a problemFND-1037269601
02HumanNon-randomized trialEfficacy outcome
In girls with central precocious puberty, final height after triptorelin exceeded pretreatment predicted height by 4.8 cm.
In plain wordsIn girls with early puberty, final height after triptorelin exceeded pretreatment predictions by 4.8 cm.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseGirls final height versus pretreatment prediction
Study
n = 58
Comparator
Predicted height before treatment
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Final height improvement
4.8 cm
versus pretreatment predicted height
Source sentences
Summary
In girls, FH was improved by 4.8 +/- 5.8 cm compared with predicted height before treatment and by 8.3 cm by comparison with a historical group.
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the long term results of 58 girls and 8 boys uniformly treated with triptorelin slow release formulation (Decapeptyl, triptorelin-SR) for CPP and compared their FH with predicted height before treatment and with the FH of a historical group of patients not treated with GnRH agonist.
Report a problemFND-1037269602
03HumanNon-randomized trialEfficacy outcome
In boys with central precocious puberty, final height after triptorelin was similar to pretreatment predicted height.
In plain wordsIn boys with early puberty, final height after triptorelin was similar to pretreatment predicted height.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeBoys final height versus pretreatment prediction
Study
n = 8
Comparator
Predicted height before treatment
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
In boys, comparison with a historical group revealed a 13.7-cm improvement, whereas predicted height before treatment was similar to FH.
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the long term results of 58 girls and 8 boys uniformly treated with triptorelin slow release formulation (Decapeptyl, triptorelin-SR) for CPP and compared their FH with predicted height before treatment and with the FH of a historical group of patients not treated with GnRH agonist.
Report a problemFND-1037269605
04HumanNon-randomized trialEfficacy outcome
In girls with central precocious puberty, final height after triptorelin exceeded historical untreated height by 8.3 cm.
In plain wordsIn girls with early puberty, final height after triptorelin exceeded historical untreated height by 8.3 cm.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseGirls final height versus historical controls
Study
n: not reported in source
Comparator
Historical patients without GnRH agonist treatment
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Final height improvement
8.3 cm
versus historical controls
Source sentences
Summary
In girls, FH was improved by 4.8 +/- 5.8 cm compared with predicted height before treatment and by 8.3 cm by comparison with a historical group.
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the long term results of 58 girls and 8 boys uniformly treated with triptorelin slow release formulation (Decapeptyl, triptorelin-SR) for CPP and compared their FH with predicted height before treatment and with the FH of a historical group of patients not treated with GnRH agonist.
Report a problemFND-1037269603
05HumanNon-randomized trialEfficacy outcome
In boys with central precocious puberty, final height after triptorelin exceeded historical untreated height by 13.7 cm.
In plain wordsIn boys with early puberty, final height after triptorelin exceeded historical untreated height by 13.7 cm.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseBoys final height versus historical controls
Study
n: not reported in source
Comparator
Historical patients without GnRH agonist treatment
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Final height improvement
13.7 cm
versus historical controls
Source sentences
Summary
In boys, comparison with a historical group revealed a 13.7-cm improvement, whereas predicted height before treatment was similar to FH.
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the long term results of 58 girls and 8 boys uniformly treated with triptorelin slow release formulation (Decapeptyl, triptorelin-SR) for CPP and compared their FH with predicted height before treatment and with the FH of a historical group of patients not treated with GnRH agonist.
Report a problemFND-1037269604

Studies that did not test the peptide alone3

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther
In triptorelin-treated girls, a higher initial bone age/statural age ratio was independently linked to lower final height.
In plain wordsIn triptorelin-treated girls, a higher initial bone age/statural age ratio was linked to lower final height.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseFinal height association with bone age/statural age ratio
Study
n = 58
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Three variables were independently associated with FH in girls: the bone age/statural age ratio at the onset of treatment (negatively), the height SD score at the end of treatment, and the posttreatment growth spurt (delta FH - height at the end of treatment).
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the long term results of 58 girls and 8 boys uniformly treated with triptorelin slow release formulation (Decapeptyl, triptorelin-SR) for CPP and compared their FH with predicted height before treatment and with the FH of a historical group of patients not treated with GnRH agonist.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1037269606
07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther
In triptorelin-treated girls, height SD score at treatment end was independently associated with final height.
In plain wordsIn triptorelin-treated girls, height score at treatment end was linked to final height.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedFinal height association with end-treatment height score
Study
n = 58
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Three variables were independently associated with FH in girls: the bone age/statural age ratio at the onset of treatment (negatively), the height SD score at the end of treatment, and the posttreatment growth spurt (delta FH - height at the end of treatment).
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the long term results of 58 girls and 8 boys uniformly treated with triptorelin slow release formulation (Decapeptyl, triptorelin-SR) for CPP and compared their FH with predicted height before treatment and with the FH of a historical group of patients not treated with GnRH agonist.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1037269607
08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther
In triptorelin-treated girls, the posttreatment growth spurt was independently associated with final height.
In plain wordsIn triptorelin-treated girls, the growth spurt after treatment was linked to final height.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedFinal height association with posttreatment growth spurt
Study
n = 58
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Three variables were independently associated with FH in girls: the bone age/statural age ratio at the onset of treatment (negatively), the height SD score at the end of treatment, and the posttreatment growth spurt (delta FH - height at the end of treatment).
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the long term results of 58 girls and 8 boys uniformly treated with triptorelin slow release formulation (Decapeptyl, triptorelin-SR) for CPP and compared their FH with predicted height before treatment and with the FH of a historical group of patients not treated with GnRH agonist.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1037269608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.